Zacks' Senior Life Sciences Analyst John Vandermosten initiates on AEON Biopharma with a $2.00 price target.
$AEON: Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar:
s27.q4cdn.com/906368049/fi...
#BiotechStocks #Biosimilars #Biologics #BotulinumToxin #ABP450 #MarketNews